Verrica Pharma的开发合作伙伴Torii Pharma获得日本厚生省批准使用YCANTH治疗传染性软疣

– Approval triggers $10 million cash milestone payment to Verrica –

– YCANTH® approval in Japan addresses significant unmet need of patients with molluscum –

– Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan –

WEST CHESTER, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that its development partner, Torii Pharmaceutical Co. Ltd. ("Torii") has received approval from the Japanese Ministry of Health, Labour and Welfare ("MHLW") for YCANTH® (TO-208) for the treatment of Molluscum Contagiosum ("molluscum"). Torii became a wholly-owned subsidiary of Shionogi & Co., Ltd., on September 1, 2025.